The Glaucoma Foundation Inc

“The chief executive officer and the assistant treasurer review form 990 in detail and then make it available to the governing board prior to being filed.”

“The organization has a board approved conflict of interest policy. Each board member must fill out an annual declaration stating they had no conflicts or identifying the nature of their interested party transactions.”

“Each year, the compensation committee reviews comparable salaries based on a recognized study and reviews the performance of the president/ceo to determine if the existing salary falls within these ranges. After a deliberation of this matter, a new proposed salary and benefit package is voted on. The minutes of the board of directors reflect the nature of this process.”

“Each year, the compensation committee reviews comparable salaries based on a recognized study and reviews the performance of the president/ceo to determine if the existing salary falls within these ranges. After a deliberation of this matter, a new proposed salary and benefit package is voted on. The minutes of the board of directors reflect the nature of this process.”

“Maine, maryland, massachusetts, michigan, minnesota, mississippi, new hampshire, new jersey, new mexico, north carolina, north dakota, ohio, oklahoma, oregon, pennsylvania, rhode island, south carolina, tennessee, utah, virginia, washington, west virginia, wisconsin”

“The organization makes its public documents, conflict of interest policy, and financial statements available to public.”

“The glaucoma foundation, inc. Is an international not-for-profit organization dedicated to eradicating glaucoma, the leading cause of preventable blindness. The strategy to achieve this goal is two-fold: raise public awareness concerning the necessity of routine eye exams, and fund critical research to find cures for glaucoma.”

“1) multiple webinars: what do cold hands have to do with glaucoma? The promise of optic nerve regeneration; the body-eye relationship how to save the sight of patients with glaucoma while minimizing adverse reaction from eye drops; insights into glaucoma & women's health: exploring the impact of menopause and visual function; glaucoma and lifestyle. 2) the optic nerve rescue and restoration think tank "a patient-centric approach while incorporating the latest science" glaucoma data integration: overview of databases available to advance glaucoma knowledge; lessons learned about glaucoma from the uk biobank; poag genomic architecture; a 360-degree biomedical profile of health: lessons from cardiovascular disease. 3) drug re-purposing in glaucoma: insulin signaling and; metformin and glaucoma; glp-1r agonists and glaucoma. 4) overview of glaucoma neuroprotection agents: why do we not have a neuroprotection agent for glaucoma? How can ai help facilitate randomized clinical trials in neuroprotection? 5) sex hormones and glaucoma: the role of sex hormones in the pathogenesis of open-angle glaucoma: evidence from epidemiological studies; estrogen signaling pathways in glaucoma; the biomechanical argument that estrogen plays a role in glaucoma; 6) non-iop factors of importance in glaucoma: diet and glaucoma; hypertension, antihypertensive drugs and glaucoma; the impact of glaucoma on activities of daily living. 7) what can tgf do to help patients, researchers, and eyecare providers tackle glaucoma?: what is the glaucoma foundation doing now? What do patients want to see in glaucoma research? 8) start with the young: info session on glaucoma for middle and high school students; in coordination with the stem institute at the city college of new york. 9) newsletters: tgf produced six electronic newsletters that were distributed to more than 16,000 households. Tgf's quarterly printed newsletters were available for constituents who do not use computers or who prefer to read paper documents. Newsletters include interviews with doctors, researchers, and patients. They cover topics such as advancements in diagnosis and treatment, perspectives on care, and personal stories of living with the disease.”

“1) genetic predisposition and ophthalmic outcomes; 2) optic nerve regeneration; 3) using artificial intelligence to reveal blood pressure's role in glaucoma progression; 4) ee-purposing an "old" drug for a new indication: elucidating the peripheral and central effects of glucagon-like peptide 1 receptor agonists to treat glaucoma; 5) search for functional loxl1 risk alleles with bit-starr; 6) vascular genotype-phenotype association in primary open-angle glaucoma; 7) investigating the role of impaired mitochondrial dynamics in exfoliation glaucoma; 8) uncovering the potential of pericytes as therapeutic targets for glaucoma; 9) nicotinamide and pyruvate for neuroenhancement in open-angle glaucoma: a phase 2 randomized clinical trial.”